Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome PharmaphorumLundbeck has reported positive trial results with Cushing's therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years.Rare DiseaseRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Lundbeck has reported positive trial results with Cushing’s therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic diseaseNext: Eisai claims UK grant to expand manufacturing site Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
